A 3-year-old boy from rural Maharashtra presents with recurrent episodes of hypoglycemia, hepatomegaly, and developmental delay. Investigations show elevated plasma acylcarnitines, reduced ketone bodies despite fasting, and normal blood ammonia. Urine organic acids reveal dicarboxylic aciduria. A diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is suspected. What is the most appropriate immediate management step?

Explanation

## Clinical Context MCAD deficiency is an autosomal recessive disorder of fatty acid β-oxidation affecting medium-chain (C6–C10) fatty acid metabolism. The clinical presentation—fasting hypoglycemia, hepatomegaly, and elevated acylcarnitines with reduced ketogenesis—is pathognomonic. ## Pathophysiology of MCAD Deficiency **Key Point:** MCAD catalyzes the first dehydrogenation step in the β-oxidation of medium-chain fatty acids. Loss of this enzyme blocks energy production from fat during fasting, leading to: - Severe hypoglycemia (impaired gluconeogenesis due to ATP depletion) - Accumulation of medium-chain acylcarnitines (diagnostic marker) - Reduced ketone body production (paradoxical for fasting state) - Hepatic steatosis from shunting of fatty acids to triglyceride synthesis ## Management Strategy **High-Yield:** The cornerstone of MCAD management is **prevention of metabolic decompensation** through: 1. **Immediate:** Intravenous dextrose to abort hypoglycemic crisis and provide energy substrate that bypasses the defective β-oxidation pathway 2. **Avoidance of fasting:** Frequent meals (every 3–4 hours) with carbohydrate-rich foods 3. **Emergency protocols:** Parents must be counseled on recognizing early signs (lethargy, poor feeding) and accessing IV dextrose quickly 4. **Genetic testing:** Confirms diagnosis (ACADM gene mutations) and enables family screening **Clinical Pearl:** Unlike other fatty acid oxidation disorders, MCAD patients typically do NOT require carnitine supplementation acutely—the block is enzymatic, not carnitine-dependent. L-carnitine may be considered in chronic management but is not first-line in acute presentation. ## Why This Answer Option 1 (IV dextrose + fasting avoidance + counseling) addresses the immediate life-threatening hypoglycemia and establishes the long-term preventive strategy. Genetic testing confirms diagnosis but is secondary to stabilization. ## Table: MCAD vs. Other Fatty Acid Oxidation Disorders | Feature | MCAD | VLCAD | CPT-II | Carnitine Deficiency | | --- | --- | --- | --- | --- | | Chain length affected | C6–C10 | C12–C20 | Transport defect | Systemic | | Ketones in fasting | ↓↓ (paradoxical) | ↓ | ↓ | ↓ | | Acylcarnitines | Medium-chain ↑ | Very long-chain ↑ | Long-chain ↑ | All ↑ | | Carnitine response | No | Yes | Yes | Yes | | First-line management | Avoid fasting, IV glucose | Carnitine, MCT diet | Carnitine, avoid fasting | Carnitine replacement | **Mnemonic:** **MCAD = Meals, Carbohydrates, Avoid fasting, Dextrose**